Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA and GPRC5D Combination CAR-T Cell Therapy in High-Risk Multiple Myeloma or Plasmacytoma
NCT06429150Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in multiple myeloma (MM) and plasmacytoma, sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Percentage of patients with treatment related adverse effects at 1 month. Planned start Dec 2026; status: not yet recruiting.
02
Conditions
multiple myeloma (MM)plasmacytoma
Beyond the preview
Go deeper on NCT06429150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06429150.